Navigation Links
Mithridion Announces Progress With Drugs for Alzheimer's Disease and Schizophrenia
Date:11/12/2009

MADISON, Wis., Nov 12 /PRNewswire/ -- Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia. New product options have been developed for MCD-386, a clinical-stage drug candidate with "first-in-class" potential for improving memory and cognition in AD, improving cognition in schizophrenia, and for disease-modifying effects (or stopping disease progression) in AD. The new product options, all in preclinical research, include MCD-386 Forte (a high dose version), MCD-386 Transderm (potentially deliverable via a skin patch), and MCD-396 Forte/Transderm, combining the benefits of both technologies.

Mithridion also announced progress in laboratory studies demonstrating the potential disease-modifying activity of its drug leads, or their ability to stop or slow down the disease processes in AD. No currently available drug treats the underlying causes of AD, and this is a major unmet clinical need.

Trevor M Twose, CEO, will present these results in a corporate overview on Thursday November 12, 2009, at 12:05 p.m. at the 7th Annual MidAmerica Healthcare Venture Forum taking place on November 11-12, 2009, at the Monona Terrace conference center in Madison, WI. Mithridion is seeking major pharmaceutical company partners to develop its expanded product options. Dr. Twose will be available for one-on-one meetings.

Mithridion is currently developing a controlled release formulation of MCD-386 (MCD-386CR) for Alzheimer's disease. The first part of Phase I clinical trials was completed in late 2008, as previously announced. The company plans to evaluate the safety, tolerability and pharmacokinetics of MCD-386CR in a randomized, double-blind, placebo-controlled, ascending multiple-dose Phase Ib study to commence in the fourth quarter of 2009.

MCD-386 Forte is a new high-dose product option, designed to maximize the disease-modifying potential of MCD-386.

The Transderm technology is designed to deliver MCD-386 or MCD-386 Forte via a skin patch, offering convenience to patients and caregivers, as well as further performance benefits.

Mithridion has proven the feasibility of these new product options in preclinical testing in laboratory models, not only for MCD-386, but also for one of the company's new drug leads described below.

Mithridion now has strong evidence in a laboratory animal model that its drug leads activate a key targeted signaling pathway that they were designed to activate. This builds upon previous research in vitro, in cell lines, demonstrating multiple modes of potential disease-modifying actions. Furthermore, in a transgenic mouse model of AD, one of Mithridion's drug leads reduced the amount of A-beta peptide, a major contributor to the dysfunction and death of neurons, in the hippocampus, a memory center of the brain.

In its next-generation drug leads, currently in preclinical research, Mithridion has been successful in enhancing further the disease-modifying attributes for AD, and has been successful in adding new attributes potentially enhancing the profile of activity for treating not only cognitive impairment, but also psychotic symptoms in schizophrenia.

Trevor M. Twose, Ph.D., Chief Executive Officer of Mithridion commented on the results, "We are very encouraged with progress. The demonstration of multiple modes of potential disease-modifying actions means that our drug leads should be able to treat the underlying causes of neuron death in AD, even if several processes contribute to it, which seems likely. Not only do we now have an important proof of this concept in vivo, but also we have been able to use this knowledge to create exciting next generation drug leads for treating AD and schizophrenia. We are actively seeking major pharmaceutical company partners for our greatly expanded portfolio of product options."

About Alzheimer's Disease (AD)

Alzheimer's disease is a progressive and fatal brain disease that destroys brain cells, causing problems with memory, thinking and behavior. Five million Americans suffer from AD today, and the number is expected to grow significantly. The market for AD drugs exceeds $4 billion, and may grow to greater than $10 billion with the development of drugs that are more effective.

The development of MCD-386 was supported in part by NIH SBIR grant AG20454 from the National Institute of Aging, and the RAID Program. The development of drugs for schizophrenia is being supported in part by NIH SBIR grant MH67430 from the National Institute of Mental Health The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Aging, National Institute of Mental Health, or the National Institutes of Health.

SOURCE Mithridion, Inc.


'/>"/>
SOURCE Mithridion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
2. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
3. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
4. Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product Candidate at the 2009 ASH Annual Meeting
5. Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon
6. EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits
7. Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps
8. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
9. Natural Alternatives International, Inc. Announces Filing of Patent Infringement Lawsuit
10. Nutri-Force Nutrition Announces the Completion of Its New Manufacturing Facility
11. Stryker Announces Agreements To Acquire Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017  This ... US$ Thousand by the following Products: ... analyzed in the report include Pharmaceuticals, and Agrochemicals. The ... Japan , Europe , ... provided for the period 2015 through 2022. Also, a ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis ... the global Urinary Incontinence market. The research answers the following ... marketed for Urinary Incontinence and their clinical attributes? How are they ...
(Date:2/23/2017)... Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... innovative proprietary products for the urology market, will release ... ended December 31, 2016 before the market open on ... will host a conference call and webcast to discuss ... 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
(Date:2/23/2017)... ... 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce ... a longtime supporter of the event. , "We are pleased that KLS Martin is ... Havlik, 2017 ACPA President. "KLS Martin has a long track record of support of ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare ... for those in the fight against cancer, has produced a seminal study that ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through the ...
(Date:2/23/2017)... York (PRWEB) , ... February 23, 2017 , ... Curemark, ... the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now ... clinical sites already enrolling children across the United States. , “There are currently ...
Breaking Medicine News(10 mins):